Myrtelle, Inc.

Myrtelle to Share First-Year Insights from FDA's START Pilot Program for Rare Disease Therapies at ASGCT 2025

- Myrtelle Inc. will present at ASGCT's Annual Meeting on May 15, 2025, highlighting its experience as one of only three gene therapy developers selected for the FDA's START Pilot Program. - The START Program enables accelerated development of rare disease treatments through enhanced regulatory communication, directly benefiting Myrtelle's gene therapy (rAAV-Olig001-ASPA) for fatal childhood Canavan disease. - Myrtelle's innovative therapy delivers a functional ASPA gene using a proprietary oligodendrocyte-targeting AAV vector, potentially restoring brain development in children with Canavan disease who currently have only palliative treatment options.